This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Study Type
OBSERVATIONAL
Enrollment
8
Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Complete Pathologic Response (pCR)
The primary aim of this feasibility study is to determine whether breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC) can accurately predict complete pathologic response (pCR) in women with biopsyproven triple negative or HER2+ breast cancer.
Time frame: 6 Months Post Surgery
Complications and Side Effects of the Needle Biopsy Procedure after NAC
Incidence of Adverse Events
Time frame: 6 Months Post Surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.